Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK3003891A RSV Vaccine in Healthy Women
NCT02360475Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Mar 2015; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02360475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360475.